Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.
Surgical removal of the thymus gland. (Dorland, 28th ed)
Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.
An encapsulated lymphatic organ through which venous blood filters.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
Dermatologic disorders attendant upon non-dermatologic disease or injury.
A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection.
Stable chromium atoms that have the same atomic number as the element chromium, but differ in atomic weight. Cr-50, 53, and 54 are stable chromium isotopes.
The transference of a kidney from one human or animal to another.
Stable iodine atoms that have the same atomic number as the element iodine, but differ in atomic weight. I-127 is the only naturally occurring stable iodine isotope.
A type of irritant dermatitis localized to the area in contact with a diaper and occurring most often as a reaction to prolonged contact with urine, feces, or retained soap or detergent.
The grafting of skin in humans or animals from one site to another to replace a lost portion of the body surface skin.
The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA.
Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use.
Tissue, organ, or gamete donation intended for a designated recipient.
Non-cadaveric providers of organs for transplant to related or non-related recipients.
Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients.
Bone-marrow-derived, non-hematopoietic cells that support HEMATOPOETIC STEM CELLS. They have also been isolated from other organs and tissues such as UMBILICAL CORD BLOOD, umbilical vein subendothelium, and WHARTON JELLY. These cells are considered to be a source of multipotent stem cells because they include subpopulations of mesenchymal stem cells.
The vessels carrying blood away from the capillary beds.
Enlarged and tortuous VEINS.
Radiographic visualization or recording of a vein after the injection of contrast medium.
Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
A vocabulary database of universal identifiers for laboratory and clinical test results. Its purpose is to facilitate the exchange and pooling of results for clinical care, outcomes management, and research. It is produced by the Regenstrief Institute. (LOINC and RELMA [Internet]. Indianapolis: The Regenstrief Institute; c1995-2001 [cited 2002 Apr 2]. Available from http://www.regenstrief.org/loinc)
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
The amount of BLOOD pumped out of the HEART per beat, not to be confused with cardiac output (volume/time). It is calculated as the difference between the end-diastolic volume and the end-systolic volume.
The hemodynamic and electrophysiological action of the left HEART VENTRICLE. Its measurement is an important aspect of the clinical evaluation of patients with heart disease to determine the effects of the disease on cardiac performance.
Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
An oxide of aluminum, occurring in nature as various minerals such as bauxite, corundum, etc. It is used as an adsorbent, desiccating agent, and catalyst, and in the manufacture of dental cements and refractories.
Compounds similar to hydrocarbons in which a tetravalent silicon atom replaces the carbon atom. They are very reactive, ignite in air, and form useful derivatives.
Exclusive legal rights or privileges applied to inventions, plants, etc.
An organism that, as a result of transplantation of donor tissue or cells, consists of two or more cell lines descended from at least two zygotes. This state may result in the induction of donor-specific TRANSPLANTATION TOLERANCE.
A chain of islands, cays, and reefs in the West Indies, lying southeast of Florida and north of Cuba. It is an independent state, called also the Commonwealth of the Bahamas or the Bahama Islands. The name likely represents the local name Guanahani, itself of uncertain origin. (From Webster's New Geographical Dictionary, 1988, p106 & Room, Brewer's Dictionary of Names, 1992, p45)
Common name for many members of the FALCONIFORMES order, family Accipitridae, generally smaller than EAGLES, and containing short, rounded wings and a long tail.
Transmission of live or pre-recorded audio or video content via connection or download from the INTERNET.
An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
The hollow, muscular organ that maintains the circulation of the blood.
The transference of a heart from one human or animal to another.
Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
An experimental animal model for central nervous system demyelinating disease. Inoculation with a white matter emulsion combined with FREUND'S ADJUVANT, myelin basic protein, or purified central myelin triggers a T cell-mediated immune response directed towards central myelin. The pathologic features are similar to MULTIPLE SCLEROSIS, including perivascular and periventricular foci of inflammation and demyelination. Subpial demyelination underlying meningeal infiltrations also occurs, which is also a feature of ENCEPHALOMYELITIS, ACUTE DISSEMINATED. Passive immunization with T-cells from an afflicted animal to a normal animal also induces this condition. (From Immunol Res 1998;17(1-2):217-27; Raine CS, Textbook of Neuropathology, 2nd ed, p604-5)
A general term indicating inflammation of the BRAIN and SPINAL CORD, often used to indicate an infectious process, but also applicable to a variety of autoimmune and toxic-metabolic conditions. There is significant overlap regarding the usage of this term and ENCEPHALITIS in the literature.
An abundant cytosolic protein that plays a critical role in the structure of multilamellar myelin. Myelin basic protein binds to the cytosolic sides of myelin cell membranes and causes a tight adhesion between opposing cell membranes.
A medical specialty concerned with the diagnosis and treatment of diseases of the internal organ systems of adults.
An antigen solution emulsified in mineral oil. The complete form is made up of killed, dried mycobacteria, usually M. tuberculosis, suspended in the oil phase. It is effective in stimulating cell-mediated immunity (IMMUNITY, CELLULAR) and potentiates the production of certain IMMUNOGLOBULINS in some animals. The incomplete form does not contain mycobacteria.
An acute or subacute inflammatory process of the CENTRAL NERVOUS SYSTEM characterized histologically by multiple foci of perivascular demyelination. Symptom onset usually occurs several days after an acute viral infection or immunization, but it may coincide with the onset of infection or rarely no antecedent event can be identified. Clinical manifestations include CONFUSION, somnolence, FEVER, nuchal rigidity, and involuntary movements. The illness may progress to COMA and eventually be fatal. (Adams et al., Principles of Neurology, 6th ed, p921)

Immunological control of a murine gammaherpesvirus independent of CD8+ T cells. (1/1079)

Adult thymectomized C57 BL/6J mice were depleted of T cell subsets by MAb treatment either prior to, or after, respiratory challenge with murine gammaherpesvirus-68. Protection against acute infection was maintained when either the CD4+ or the CD8+ T cell population was greatly diminished, whereas the concurrent removal of both T cell subsets proved invariably fatal. The same depletions had little effect on mice with established infection. The results indicate firstly that both CD4+ and CD8+ T cells play a significant part in dealing with the acute infection, and secondly that virus-specific antibody contributes to controlling persistent infection with this gammaherpesvirus.  (+info)

Long-term results of pancreas transplantation under tacrolius immunosuppression. (2/1079)

BACKGROUND: The long-term safety and efficacy of tacrolimus in pancreas transplantation has not yet been demonstrated. The observation of prolonged pancreatic graft function under tacrolimus would indicate that any potential islet toxicity is short-lived and clinically insignificant. We report herein the results of pancreas transplantation in patients receiving primary tacrolimus immunosuppression for a minimum of 2 years. METHODS: From July 4, 1994 until April 18, 1996, 60 patients received either simultaneous pancreas-kidney transplant (n=55), pancreas transplant only (n=4), or pancreas after kidney transplantation (n=1). Baseline immunosuppression consisted of tacrolimus and steroids without antilymphocyte induction. Azathioprine was used as a third agent in 51 patients and mycophenolate mofetil in 9. Rejection episodes within the first 6 months occurred in 48 (80%) patients and were treated with high-dose corticosteroids. Antilymphocyte antibody was required in eight (13%) patients with steroid-resistant rejection. RESULTS: With a mean follow-up of 35.1+/-5.9 months (range: 24.3-45.7 months), 6-month and 1-, 2-, and 33-year graft survival is 88%, 82%, 80%, and 80% (pancreas) and 98%, 96%, 93%, and 91% (kidney), respectively. Six-month and 1-, 2-, and 3-year patient survival is 100%, 98%, 98%, and 96.5%. Mean fasting glucose is 91.6+/-13.8 mg/dl, and mean glycosylated hemoglobin is 5.1+/-0.7% (normal range: 4.3-6.1%). Mean tacrolimus dose is 6.5+/-2.6 mg/day and mean prednisone dose 2.0+/-2.9 mg/day at follow-up. Complete steroid withdrawal was possible in 31 (65%) of the 48 patients with functioning pancreases. CONCLUSIONS: These data show for the first time that tacrolimus is a safe and effective long-term primary agent in pancreas transplantation and provides excellent long-term islet function without evidence of toxicity while permitting steroid withdrawal in the majority of patients.  (+info)

Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. (3/1079)

We report the results of the first prospective randomized multicenter study of immunosuppressive treatment in patients with previously untreated nonsevere aplastic anemia (AA) as defined by a neutrophil count of at least 0.5 x 10(9)/L and transfusion dependence. Patients were randomized to receive cyclosporin (CSA) alone or the combination of horse antithymocyte globulin ([ATG] Lymphoglobuline; Merieux, Lyon, France) and CSA. The endpoint of the study was the hematologic response at 6 months. One hundred fifteen patients were randomized and assessable with a median follow-up period of 36 months; 61 received CSA and 54 ATG and CSA. In the CSA group, the percentage of complete and partial responders was 23% and 23%, respectively, for an overall response rate of 46%. A significantly higher overall response rate of 74% was found in the ATG and CSA group, with 57% complete and 17% partial responders (P =. 02). Compared with CSA alone, the combination of ATG and CSA resulted in a significantly higher median hemoglobin level and platelet count at 6 months. Fewer patients required a second course of treatment before 6 months due to a nonresponse. In the CSA group, 15 of 61 (25%) patients required a course of ATG before 6 months because of disease progression, compared with only 3 of 54 (6%) in the ATG and CSA group. The survival probabilities for the two groups were comparable, 93% (CSA group) and 91% (ATG and CSA group), but at 180 days, the prevalence of patients surviving free of transfusions, which excluded patients requiring second treatment because of nonresponse, death, disease progression, or relapse, was 67% in the CSA group and 90% in the ATG and CSA group (P =.001). We conclude that the combination of ATG and CSA is superior to CSA alone in terms of the hematologic response, the quality of response, and early mortality, and a second course of immunosuppression is less frequently required.  (+info)

Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. (4/1079)

To determine whether the antigen-driven T-cell response is involved in the pathogenesis of aplastic anemia (AA), we examined the complementarity-determining region 3 (CDR3) size distribution of T-cell receptor (TCR) beta-chain (BV) subfamilies in the bone marrow (BM) of untreated AA patients. AA patients who did not respond to immunosuppressive therapy and those who obtained unmaintained remission early after cyclosporine (CyA) or antithymocyte globulin (ATG) therapy exhibited essentially a normal CDR3 size pattern. In contrast, five patients who needed continuous administration of CyA to maintain remission exhibited a skewed CDR3 size pattern in a number (>40%) of BV subfamilies suggestive of clonal predominance. The skewing of CDR3 size distribution became less pronounced in one of the CyA-dependent patients when the patient achieved unmaintained remission after a 4-year therapy with CyA, whereas it persisted longer than 7 years in the other patient requiring maintenance therapy. Sequencing of BV15 cDNA for which the CDR3 size pattern exhibited apparent clonal predominance in all CyA-dependent patients showed high homology of the amino acid sequence of the CDR3 between two different patients. These findings indicate that antigen-driven expansion of T cells is involved in the pathogenesis of AA characterized by CyA-dependent recovery of hematopoiesis.  (+info)

Late graft failure 8 years after first bone marrow transplantation for severe acquired aplastic anemia. (5/1079)

A 14-year-old patient with acquired very severe aplastic anemia (VSAA) underwent bone marrow transplantation (BMT) from his HLA-identical brother. Preparative therapy was cyclophosphamide (CY) 200 mg/kg over 4 days. GVHD prophylaxis was with cyclosporin A (CsA) for a year. After an 8 year follow-up during which the patient was well with normal blood counts, graft failure occurred. At this time marrow chimerism studies demonstrated that 85% of hemopoiesis was of recipient origin. The patient was re-engrafted from the same donor after conditioning with CY 200 mg/kg over 4 days plus rabbit antithymocyte globulin (ATG) 3.5 mg/kg/day for 3 days. After 140 days follow-up he has a normal blood count. The possible causes of the graft failure are discussed. This case demonstrates that, although rarely, very late graft failure may occur after BMT for AA and highlights the need for long-term monitoring even in apparently successfully transplanted patients.  (+info)

Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. (6/1079)

The present study was undertaken to acquire a rationale for clinical dose adjustment of anti-thymocyte globulin (ATG) to improve cost effectiveness and safety of graft-versus-host disease prophylaxis. The concentration of rabbit ATG in the serum of 12 patients was measured by ELISA and by the inhibitory effect on phytohaemagglutinin-induced blastogenesis. At 10 mg/ml ATG, 3H-thymidine incorporation was effectively blocked. Serial two-fold dilution of ATG showed that this effect decreased in a concentration-dependent manner and was lost at 10 ng/ml ATG. One hundred microlitres serum taken at day -1 to +22 post transplant effected significant inhibition of the phytohaemagglutinin-response with 49+/-12% c.p.m. (x +/- s.d.) on day +1 post transplant compared to 93+/-13% c.p.m. on day -1 (P<0.001, unpaired one-sided t-test). The rabbit-IgG was maximal at a concentration of 907+/-187 microl/ml at day 0. Subsequently, it decreased with time. While rabbit-IgG was detectable for a long period (e.g. 160 microg/ml at day +22 in patient MD), the effect on the phytohaemagglutinin-response of normal mononuclear cells lasted up to 4 days post transplant. We conclude that 90 mg/kg body weight ATG-Fresenius given prior to marrow transplant leads to sustained T cell immunosuppression post transplant.  (+info)

Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow. (7/1079)

A five-agent GVHD prophylaxis programme consisting of cyclosporin A, methotrexate, anti-thymocyte-globulin, pentaglobin and metronidazol was given to 48 recipients of unrelated donor marrow with chronic myelogenous leukemia, acute leukemia, myelodysplastic syndromes, and familiar lymphocytic hemophagocytosis of an average age of 33.5 (0.6-56) years. GVHD grades II-IV occurred in 18 patients (39%) and grades III-IV in five patients (11%). Chronic GVHD developed in nine patients (23%), three limited and six extensive. Fifteen patients died. Clinical relapse was detected in eight patients. Four patients died as a consequence of the underlying disease and subsequent treatment, 11 patients died of transplant-related causes. After a median follow-up of 19 months, the overall and disease-free survival are 67% and 62%, respectively. Survival by age is as follows: 0-19 years: 12/13 patients; 20-39 years: 14/25 patients; 40-59 years: 7/10 patients. The five-agent GVHD prophylaxis regimen is effective. Matched-unrelated donor transplants can be carried out safely in patients younger than 50 years of age. The results in patients younger than 20 years of age should encourage matched-unrelated donor transplants at earlier stages of the disease.  (+info)

L-Arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. (8/1079)

BACKGROUND: Mesangial cell lysis in the antithymocyte serum (ATS)-induced model of glomerulonephritis is dependent on the generation of cytotoxic nitric oxide (NO) through transient induction of NO synthase (iNOS). We hypothesized that increased availability of L-arginine (L-Arg) during mesangial cell lysis might provide iNOS with increased substrate leading to increased lysis, and that this increased lysis would be reflected in more severe fibrotic disease at day 6. METHODS: To ensure whole body equilibration with high L-Arg at the time of injury, rats were pretreated with 1% L-Arg in drinking water for one week prior to the administration of ATS. Animals were sacrificed six hours after ATS injection when previous experiments had indicated iNOS induction had occurred and at six days. At six hours, plasma was obtained for L-Arg levels and nitrite/nitrate (NOx) content. Renal tissues were taken for histological evaluation of glomerular cell counts, macrophage infiltration (ED-1), and iNOS expression. Glomeruli were isolated for detection of iNOS mRNA and placed in culture to study the dependence of NO production on L-Arg concentration. In rats sacrificed at six days, L-Arg supplementation was stopped 16 hours after ATS injection. Fibrotic disease was evaluated by urinary protein excretion, histological assessment of glomerular cell number, matrix accumulation, and production of transforming growth factor-beta1 and matrix components fibronectin and plasminogen activator inhibitor type-1 (PAI-1) by isolated glomeruli in culture. RESULTS: At six hours, the glomerular cell number was significantly reduced by ATS injection (P < 0.01) and further significantly (P < 0. 05) reduced by L-Arg feeding [normal control (NC) = 64.2 +/- 1, ATS = 53.4 +/- 0.7, ATS + L-Arg = 50.8 +/- 0.7]. Disease increased macrophage infiltration and iNOS protein and iNOS mRNA levels markedly (P < 0.01), whereas L-Arg feeding did not further increase these variables. Plasma L-Arg levels (nmol/ml) were reduced by disease (NC = 121 +/- 9, ATS = 84 +/- 13, P < 0.01) and elevated by L-Arg feeding (ATS + L-Arg = 166 +/- 12, P < 0.01). Plasma NOx was significantly increased by ATS and further increased by ATS + L-Arg (P < 0.05). Production of NOx by cultured glomeruli showed striking L-Arg concentration dependence in six hours but not in normal glomeruli. In the group sacrificed at day 6, day 2 proteinuria was higher in the ATS + L-Arg group compared with the ATS alone group (P < 0.05). Measures of fibrotic disease at day 6 all showed large increases over control with ATS alone (P < 0.01), and further small, but significant increases when L-Arg was combined with ATS (P < 0.05). CONCLUSIONS: The results indicate that if given during disease induction, L-Arg supplementation can enhance iNOS-dependent tissue injury by providing increased substrate. Although the increase in injury with L-Arg supplementation was small, it led to increased fibrosis at day 6. These data predict that in diseases with repeated iNOS-dependent tissue injury, L-Arg supplementation may produce cumulative increases in tissue fibrosis.  (+info)

Drug = A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs); ACICLOVIR; AMG531; AMIKACIN; AMPHOTERICINE B, LIPOSOME; AP1903; AP1903 A594; ATG; ATG conditioning regimen; ATG+Rapamune+cyclosporine; ATG+cyclosporine; ATG-Fresenius; ATG-fresenius; Abatacept; Acetate; Aciclovir; Alefacept; Alemtuzumab; Alemtuzumab (Campath ); Alemtuzumab and Rituximab; Alkeran; Allogeneic donor derived B-lymphocytes; Alpha beta depletion; Amikacin; Androgens; Anti-CD45; Anti-Thymocyte Globulin; Anti-Thymocyte Globulin (Rabbit); Anti-thymocyte globulin; Anti-thymocyte globulin (horse); Anti-thymocyte globulin (rabbit); Antilymphocyte serum; Antithymocyte Globulin; Antithymocyte Globulin (ATG); Antithymocyte globulin; Antithymocyte globulin (Rabbit); Atgam; BL-8040; BPX-501; BPX-501 cells; BUSULFAN; Bone marrow derived mesenchymal stem cells; Busilvex; Busulfan; Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.; ...
Epstein-Barr virus (EBV) associated lymphoproliferative disorder (LPD) after immunosuppressive therapy for aplastic anemia (AA) is extremely rare in a nontransplant setting and has not been well described. This report describes a severe AA patient in whom fatal EBV-LPD developed after being treated with rabbit antithymocyte globulins (ATG) and cyclosporine A (CsA). An 81-year-old man was diagnosed as having severe AA. He was started on CsA followed by administration of ATG for five consecutive days. One month after the start of ATG, persistent fever which was not responsive to antibiotics or antifungal agents developed and atypical lymphocytes emerged in peripheral blood. Repeated blood cultures were negative. An extremely high level of EBV virus in his peripheral blood plasma was detected by means of a quantitative real-time PCR assay. Even after the cessation of CsA, the fever persisted and the peripheral atypical lymphocytes proliferated rapidly. The patient suffered from respiratory failure, liver
Anti-lymphocyte globulin (ALG) is an infusion of animal- antibodies against human T cells which is used in the treatment of acute rejection in organ transplantation. Its use was first reported by Thomas Starzl in 1966. Its use in transplant was supplanted by thymoglobulin between 1984 and 1999. It has also been used in the treatment of aplastic anemia. It is less commonly used than the similar anti-thymocyte globulin (ATG), and like ATG it is associated with cytokine release syndrome in the short term and an increased risk of post-transplant lymphoproliferative disorder in the long term. ALG is more likely to cause side effects than ATG, but is safer than OKT3. The product was manufactured by Upjohn and Merieux, as well as the Schweizerisches Serum- und Impfinstitut in Bern, the latter of which was made by injecting horses with human thoracic duct lymphocytes and was called Lymphoser Berna. Hakim, Nadey; Danovitch, Gabriel (2013). Transplantation Surgery. Springer Science & Business Media. p. ...
Definition of antithymocyte globulin in the Financial Dictionary - by Free online English dictionary and encyclopedia. What is antithymocyte globulin? Meaning of antithymocyte globulin as a finance term. What does antithymocyte globulin mean in finance?
Australian Medicines Handbook section 14.5.3 Anti-thymocyte globulin is indicated for the prophylaxis of renal graft rejection as well as the treatment of steroid-resistant renal transplant rejection. Kidney transplantation is the treatment of choice for most patients with end-stage renal disease. However, 15-35% of transplant recipients will experience one episode of acute rejection in the first year. Giving antibody to deplete thymocytes (T cells) is one way to suppress the immune system to prevent or reverse graft rejection. Anti-thymocyte globulin is a polyclonal antibody against human T cells. It is a gamma immunoglobulin produced by immunising rabbits. As well as depleting T cells in the circulation, anti-thymocyte globulin is also thought to reduce T cell proliferation, homing and cytotoxic effects within the body. Depletion of T cells occurs within a day of starting intravenous treatment. This immunoglobulin has been compared to other treatments in renal transplant patients who are also ...
Vredevoe, D L. and Hays, E F., Effect of antilymphocytic and antithymocytic sera on the development of mouse lymphoma. (1969). Subject Strain Bibliography 1969. 1606 ...
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patients immune system from rejecting the donors stem cells. The donated stem cells may replace the patients immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the bodys normal cells. Giving tacrolimus, sirolimus, antithymocyte globulin, and methotrexate before and after transplant may stop this from happening.. PURPOSE: This phase II trial is studying how well sirolimus, tacrolimus, and antithymocyte globulin work in preventing graft-versus-host disease in patients undergoing a donor stem cell transplant for hematological cancer . ...
A patient with Sézary syndrome developed a diffuse undifferentiated lymphoma of T-cell origin. After becoming resistant to multiple chemotherapeutic agents, the patient was treated with antithymocyte globulin. A 75% reduction in adenopathy and complete resolution of skin erythema was observed during an 8-day period. In addition the percent of circulating T cells and the ability of those cells to respond to phytohemagglutinin and concanavalin A were reduced after antithymocyte globulin therapy. The patient died of an intracerebral hemorrhage secondary to profound thrombocytopenia. The study suggests that tumor lysis may be achieved by passive antibody therapy in certain advanced lymphomas. ...
Промежуточные результаты рандомизированного исследования посттрансплантационного циклофос- фана и кроличьего АТГ в качестве профилактики реакции трансплантат против хозяина у пациентов с миелопролиферативными заболеваниями и мие- лодиспластическим синдромUpdate on the randomized trial of post-transplanation cyclophosphamide and rabbit ATG for graft-versus-host disease prophylaxis in chronic myeloproliferative neoplasms and myelodysplastic syndrome
This trial will compare the efficacy and tolerability of antithymocyte globulin [Thymoglobulin, rabbit antithymocyte globulin], mycophenolate mofetil
View the review history for Modest dose anti-thymocyte globulin administered intraoperatively is safe and effective in kidney transplantations: a retrospective study
Detailed Anti-Thymocyte Globulin (Rabbit) dosage information for adults. Includes dosages for Renal Transplant; plus renal, liver and dialysis adjustments.
Easy to read patient leaflet for anti-thymocyte globulin (equine). Includes indications, proper use, special instructions, precautions, and possible side effects.
A cardiac explant from a man who had been severely incapacitated by chronic cardiac failure and coronary artery disease for seven years entailing fourteen admissions to hospital. On 16 May 1969 cardiac transplantation was performed. Immunosuppression was by Azathioprine, prednisolone and antilymphocyte serum. His initial progress was excellent but three months after his
Jeejeebhoy, H, Inactication of thymus and marrow-derived lymphocytes by heterologous antilymphocyte serum (als). (1971). Subject Strain Bibliography 1971. 1407 ...
Background T-cell depletion therapy is associated with diminished interleukin (IL)-7/IL-15-dependent homeostatic proliferation resulting in incomplete T-cell repopulation. Furthermore, it is associated with impaired T-cell functions. We hypothesized that this is the result of impaired cytokine responsiveness of T cells, through affected signal transducer and activator of transcription (STAT)5 phosphorylation and upregulation of coinhibitory molecules. Materials and Methods Patients were treated with T cell-depleting rabbit antithymocyte globulin (rATG) (6 mg/kg, n = 17) or nondepleting, anti-CD25 antibody (basiliximab, 2 × 40 mg, n = 25) induction therapy, in combination with tacrolimus, mycophenolate mofetil, and steroids. Before and the first year after transplantation, IL-7 and IL-2 induced STAT5 phosphorylation, and the expression of the coinhibitory molecules programmed cell death protein 1 (PD-1), T cell immunoglobulin mucin-3 (TIM-3), lymphocyte activation gene-3 (LAG-3), cytotoxic ...
The pathogenesis of type 1 diabetes in both humans and NOD mice appears dependent upon an aberrant immune response that results in the destruction of insulin-producing β-cells. While prevention of type 1 diabetes in NOD mice can be accomplished through a wide variety of monotherapies, reversal of overt disease has considerably fewer reported efficacious therapies (30,31). Of those that do show success, many combine two or more therapeutic agents to achieve this reversal (32,33). Indeed, one of the earliest demonstrations for the ability of combination therapy to reverse hyperglycemia in NOD mice utilized a somewhat similar form of murine ATG, anti-lymphocyte serum, in combination with exendin-4, to effectively reverse disease in this animal model of type 1 diabetes (14). Consequently, herein we have described an approach using two clinically relevant therapies, ATG and GCSF, for the purpose of immunomodulation that would provide benefit in terms of reversing type 1 diabetes, as demonstrated in ...
Introduction: ATG-Fresenius, a highly purified rabbit polyclonal anti-human T-lymphocyte immunoglobulin resulting from immunisation of rabbits with the Jurkat T-Lymphoblast cell line is currently used for the prevention of acute rejection in patients receiving solid organ-transplants. The aim of this study was to investigate the in vitro activity of ATG-Fresenius that underlies its activity in prevention of ischemia-reperfusion injury in solid organ transplantation.. Material and methods: Human vascular endothelial cells (HUVEC) and peripheral blood mononuclear cells (PBMCs) were isolated from umbilical vein or peripheral blood, incubated 20 to 24 h before analysis of adhesion molecule expression and use in the ATG Fresenius-binding or immune cell adhesion assays. The cells were cultured alone or activated with TNF-alpha (HUVECs) or phytohaemagglutinin (PBMCs) for 20 h. HUVEC were incubated for 30 min at 2-8 C with 10 and 100 mg/mL ATG-Fresenius (Fresenius Biotech GmbH) or reference rabbit IgG ...
This is a multi-institution, single arm, non-randomized pilot study coordinated by the Pediatric Blood and Marrow Transplant Consortium. Eligible patients will have severe combined immunodeficiency syndrome (SCID) or severe T-cell immunodeficiency disorder. Patients with these disorders do not have properly functioning immune systems. Without treatment, these disorders result in early childhood death. The standard treatment used for these diseases is to give the patient a stem cell transplant from a matched donor. The donor cells can be from a family member, an unrelated marrow donor or umbilical cord blood. The donor source will impact on transplant risks and approaches to the preparative regimen.. There have been many different preparative regimens used for patients with SCIDS or severe T-cell immunodeficiency syndromes. Some patients have gotten no preparative regimen, while others have gotten only antithymocyte globulin (ATG; immune proteins made in horses that, when given, will kill ...
Larsen JT, Hogan WJ, Micallef IN, Dispenzieri A, Gertz MA, Inwards DJ, Tun HW, Roy V, Geyer SM, Allred JB, Wu W, Ansell SM, Elliott MA, Tefferi A, Porrata LF, Gastineau DA, Lacy MQ, Litzow MR. A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin. Leuk Lymphoma. 2013 Aug; 54(8):1713-8. Epub 2012 Dec 31 ...
This study is comparing outcomes of patients who did and did not recieve antithymocyte globulin for Graft-Versus-Host-Disease prophylaxis in matched unrelated
Understand Antithymocyte Globulin (Equine), usages in various health conditions, and side effects and warnings. Explore other smart treatment options, see research evidence, and find out about peoples experiences with many popular treatments, including feedback from patients and professionals.
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant using stem cells that closely match the patients stem cells, helps stop
Specific anti-T antibody was isolated from rabbit anti-mouse and anti-rat thymocyte antiserum on immunosorbent prepared by fixation of brain homogenate in glutaraldehyde. Conditions of isolation, purity of obtained antibody and cytotoxic activity were followed. The resulting preparation containing immunoglobulin G is contaminated with beta globulin and albumin, contains non-precipitating proteins originating from brain tissue and is cytotoxic for thymocytes. Cytotoxicity for bone marrow cells was not demonstrated. ...
ESN individuals also display some unconventional humoral immune responses that may play a role in HIV neutralization: a very effective protective mechanism against viral infections. Two kinds of HIV-related humoral immune responses have been described in ESN individuals so far: antibodies to cellular proteins involved in the HIV infection/entry process, and HIV-specific mucosal antibodies.. The induction of anticell immune responses is rather common, and antilymphocyte antibodies have been observed early in sera from HIV-infected patients [55-57]. As the majority of these antibodies recognize HLA or CD4 molecules, their appearance had first been attributed to the cytopathic effect of HIV infection or to the long-lasting exposure to blood derivatives, as in the case of haemophiliacs [58,59]. In this regard, HIV-blocking IgG directed against HLA class I and CD4 molecules have been found in sera of ESN individuals [60-63] (n = 14/31). Anti-CD4 antibodies of ESN individuals recognize epitopes ...
RATIONALE: Giving chemotherapy before a donor bone marrow stem cell transplant helps stop the growth of cancer cells. Chemotherapy and antithymocyte glo
Dweik BAl, Redjoul R, Bastuji-Garin S, Beckerich F, Robin C, Pautas C, Toma A, Cabanne L, Maury S, Cordonnier C Am J Hematol. 2016;91(4):E276-8. ...
臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。. To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of NTU Repository with Academic Hub to form NTU Scholars.. ...
Appreciate it! Oddly, the Professional version of the drugs.com page on Symbicort does mention inhaled corticosteroids:. MONITOR: The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than 10 mg/​day or 1 mg/​kg/​day of prednisone or equivalent for more than 2 weeks), or long-term topical or inhaled corticosteroids.. That said, a physician friend of mine responded to my similar post on FB by saying the following, so combined with the research you cite, Im inclined to think that Im fine: Theres a big difference between the dosage of ...
Find the Blink Price & Information for Thymoglobulin - as low as $23,644.91 - pick up at your pharmacy (Rite Aid, Walmart & more). Price transparency and up to 80% savings.
A lightweight gel that strengthens skin, repairs aging skin, and protects against future signs of aging. Formulated for all skin types.
This is what I understand is happening with my white blood cells, especially T-Cells. T-Cells are the dudes that really go out to destroy foreign particles in the body. We have to get them down in order for them not to attack incoming stem cells wednesday. over the past 4 days, the busulfex has essentially put the whammy on new T-Cell production. IE: there are no re-enforcements for the T-Cells. However, the busulfex only stops new production of T-Cells, therefore any T-Cells hanging around before the busulfex must be now nuked. So they use this stuff called ATG. This are Antithymocyte Globulin Rabbit antibodies. Harmless little rabbit antibodies. However, when they are injected into the patients system, they alarm the T-Cells to the max. This is what the T-Cells do: Eat the antibodies, release cytokines, hope for re-enforcements. Eating the antibodies is good. Dont need them, but they are really not a harm anyway. Releasing Cytokines will heat things up causing fever, sometimes killing the ...
TY - JOUR. T1 - Rabbit antithymocyte globulin and cyclosporine as first-line therapy for children with acquired aplastic anemia. AU - Takahashi, Yoshiyuki. AU - Muramatsu, Hideki. AU - Sakata, Naoki. AU - Hyakuna, Nobuyuki. AU - Hamamoto, Kazuko. AU - Kobayashi, Ryoji. AU - Ito, Etsuro. AU - Yagasaki, Hiroshi. AU - Ohara, Akira. AU - Kikuchi, Akira. AU - Morimoto, Akira. AU - Yabe, Hiromasa. AU - Kudo, Kazuko. AU - Watanabe, Ken Ichiro. AU - Ohga, Shouichi. AU - Kojima, Seiji. N1 - Copyright: Copyright 2013 Elsevier B.V., All rights reserved.. PY - 2013/1/31. Y1 - 2013/1/31. UR - http://www.scopus.com/inward/record.url?scp=84873544539&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84873544539&partnerID=8YFLogxK. U2 - 10.1182/blood-2012-11-465633. DO - 10.1182/blood-2012-11-465633. M3 - Letter. C2 - 23372154. AN - SCOPUS:84873544539. VL - 121. SP - 862. EP - 863. JO - Blood. JF - Blood. SN - 0006-4971. IS - 5. ER - ...
Looking for online definition of antithymocyte globulin in the Medical Dictionary? antithymocyte globulin explanation free. What is antithymocyte globulin? Meaning of antithymocyte globulin medical term. What does antithymocyte globulin mean?
We evaluated the role of granulocyte colony-stimulating factor (G-CSF) in patients with severe aplastic anemia (SAA) treated with antithymocyte globulin (ATG) and cyclosporine (CSA). Between January 2002 and July 2008, 192 patients with newly diagnosed SAA not eligible for transplantation were entered into this multicenter, randomized study to receive ATG/CSA with or without G-CSF. Overall survival (OS) at 6 years was 76% ± 4%, and event-free survival (EFS) was 42% ± 4%. No difference in OS/EFS was seen
Before treatment, allergy to ATG was determined by intradermal injection of 0.1 mL of ATG at a concentration of 5 mg/mL. Antithymocyte globulin treatment was contraindicated if erythema larger than 5 mm in diameter, compared with the saline control, developed. Eligible patients were given ATG (Pharmacia, Peapack, New Jersey), 40 mg/kg of body weight daily for 4 days. Antithymocyte globulin was administered intravenously over 4 to 8 hours with oral prednisone, 1 mg/kg daily [minimum of 40 mg/d], for 10 days and then tapered by day 17. Clinic visits were scheduled at 3, 6, and 12 months and then annually. Bone marrow aspirate, biopsy specimens, and bone marrow samples for cytogenetic analysis were obtained at 6 and 12 months and then annually. Excluding transfusions and antibiotics, patients received no other treatment for myelodysplastic syndromes for at least 6 months. The main criterion for response was independence from red blood cell transfusion. This criterion was met if 1) the patient was ...
Phillip Scheinberg, M.D., Olga Nunez, R http://dapoxetineuk.com/side-effects.html .N., B.S.N., Barbara Weinstein, R.N., Priscila Scheinberg, M.S.D., Colin O. Wu, Ph.D., and Neal S. Young, M.D.: Equine versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia Obtained aplastic anemia in the serious form is fatal without treatment.1 Severe aplastic anemia was initially treated with the advancement of stem-cell transplantation in the 1970s definitively. The serendipitous observation of autologous marrow reconstitution in a couple of sufferers with rejected grafts recommended that the conditioning brokers necessary for transplantation might themselves be therapeutic.2 Purposeful immunosuppression induced by the infusion of antithymocyte globulin , polyclonal antibodies generated in pets by inoculation with human thymocytes, became effective, with long-term survival that was similar to the outcomes of stem-cellular transplantation from a histocompatible sibling.3,4 An immune mechanism of ...
Immunosuppressive therapy is a treatment for aplastic anemia patients who are not candidates for hematopoietic stem cell transplantation. The aim of the study to evaluate the frequency and severity of immunosuppressive therapy-induced hepatotoxicity in patients with aplastic anemia. The records of 27 patients with aplastic anemia who had eceived immunosuppressive therapy were received and determined for evidence of hepatotoxicity. The patients were divided into three groups. Group 1 was treated with antithymocyte/antilymphocyte globulin and cyclosporin A, group 2 received onl yyclosporin-A and group 3 was treated with antithymocyte/antilymphocyte globulin + cyclosporin-A and granulocyte macrophage colony-stimulating factor. All patients in group 1 had an initial increase in AST and ALT levels after therapy, but these tests abnormalities returned to normal in each case (p> 0.05). There was no detectable change in AST and ALT levels in group 2 (p>0.05). In group 3, five patients had an increase in ...
Semantic Scholar extracted view of Fludarabine, cyclophosphamide, and antithymocyte globulin for a patient with dyskeratosis congenita and severe bone marrow failure. by Fabiana Ostronoff et al.
BACKGROUND AND OBJECTIVE: We previously reported that patients with acquired severe aplastic anemia (SAA) treated with antilymphocyte globulin (ALG), 6-methylprednisolone, cyclosporin A (CyA) and granulocyte colony-stimulating factor (G-CSF) can mobilize peripheral blood hemopoietic progenitors (PBHP). The aim of the present study was to assess phenotypic and functional properties of these PBHP. METHODS: We studied seven patients who underwent 43 leukophereses (median 5) between day +30 and +80 following ALG, while in treatment with CyA and G-CSF. Mobilized peripheral blood hemopoietic progenitors were analyzed using surface markers, conventional assays for clonogenic cells (CFU-GM, BFU-E, CFU-GEMM) as well as the recently developed assay for long-term culture initiating cells (LTC-ICs). RESULTS: The proportion of CD34+ cells ranged between 0% and 5.4% (median 0.3%), CD34+DR between 0% and 3.5% (median 0.1%) and CD8+ cells between 3.3% and 56% (median 31%). When light density mononuclear cells ...
BACKGROUND: Surveillance biopsies (SBs) are performed in some pediatric kidney transplant programs, based on data obtained in earlier immunosuppressive eras that the treatment of subclinical acute rejection results in better graft survival. The benefit of SBs for patients on modern immunosuppression regimens is unclear. We have therefore evaluated the clinical utility of SBs in a population of children receiving a kidney transplant. METHODS: We have performed SBs at 3, 6 and 12 months post-transplantation as standard of care at our institution since 2013 in patients on a regimen of rabbit anti-thymocyte globulin, tacrolimus, mycophenolate and rapid steroid taper (RST; steroids maintained in some exceptions ...
The incidence, causes, and impact of acute infection were analyzed among 814 consecutive patients from 24 institutions undergoing primary heart transplantation between January 1, 1990, and June 30, 1991, with mean follow- up of 8.2 months (range 0 to 18 months). Sixty-nine percent of the patients had no infections during the follow-up, whereas 31% of patients had one or more infection episodes. The cumulative incidence of infections per patient was 0.41 at 3 months, 0.55 at 6 months, and 0.62 at 12 months after transplantation. Bacterial and viral infections were most common (47% and 41% of infections), with fungi and protozoa accounting for 12%. Overall mortality per infection was 13%, but mortality with fungal infections was higher (36%, p < 0.0001). The most common organ infected was the lung, with a mortality of 23%. The probability of infection by 12 months was higher when OKT3 or antithymocyte globulin induction therapy was used (41% versus 35%, p = 0.01). The single most frequent ...
Immobilization of Raji cells on surface coated with anti-lymphocyte globulin (ALG) at low cell densities lead to the synthesis of Epstein-Barr virus (EBV) early antigen (EA) in up to 5% of the cells. At higher cell densities the percentage of antigen-positive cells decreased and at confluency no antigen synthesis was observed. Addition of iododeoxyuridine (IdUrd) to low density cultures increased the expression of EA to 20%, whereas in confluent cultures the cells could not be induced to synthesize EA. Treatment of cells in suspension with ALG failed to induced EA synthesis and did not potentiate the effect of IdUrd. Immobilized Raji cells proved to be suitable targets for superinfection with EBV derived from P3HR1 cultures. ...
NFkB p65 Rabbit anti-Human, Mouse, Rat, Polyclonal, eBioscience™ 50 μg; Unconjugated NFkB p65 Rabbit anti-Human, Mouse, Rat, Polyclonal, eBioscience™...
Non-cardiogenic pulmonary edema (NCPE) is a clinical syndrome characterized by simultaneous presence of severe hypoxemia, bilateral alveolar infiltrates on chest radiograph, without evidence of left atrial hypertension/congestive heart failure/fluid
Severe aplastic anemia (SAA) is a life-threatening blood disease that can be successfully treated with immunosuppressive drug regimens or allogeneic stem cell transplantation. However, 20-40% of patients are ineligible for transplant due to lack of an appropriate donor, age, or comorbidities. Immunosuppression can be more broadly utilized, but about 1/3 of patients do not respond to a single course of horse ATG and cyclosporine and have persistent severe cytopenias.
Alemtuzumab to Treat Severe Aplastic Anemia This study is currently recruiting participants. Verified April 2012 by National Institutes of Health Clinical…
Severe aplastic anemia (SAA) is an autoimmune disorder (AID) due to the attack of autoreactive cytotoxic T lymphocytes to the hematopoietic component of the bone marrow.
Severe Aplastic Anemia is a blood disorder where the bodys bone marrow doesnt make enough new blood cells. Learn about the new stem cell treatment option.
In the Subjects, Materials, and Methods Subjects section of this paper one reads: In February 2007, an HIV-infected patient underwent stem cell transplantation (SCT) due to a relapse of AML with a graft consisting of CCR5A32/A32 donor cells. The pre-transplant conditioning regimen included 100 mg/m2 of amsacrine, 30 mg/m2 of fludarabine, 2 g/m2 of cytarabine (day -12 until -9), 60 mg/kg of cyclophosphamide (days -4 and -3), 5.5 mg/kg of rabbit antithymocyte globuline (in three doses between day -3 and -1), and a 400 cGy total body irradiation (TBI; day -5). ART was discontinued on the day of transplantation, and 13 months later the patient received a second transplant with CCR5A32/A32 stem cells from the same donor due to a second relapse of AML. The conditioning regimen consisted of 100 mg/m2 of cytarabine (day -7 until day -1), 6 mg/m2 of gemtuzumab (day -7 and day -1), and a 200 cGy TBI (day -1)... Twelve months post-transplant, the patient underwent liver biopsy and histological examination ...
Shop a large selection of products and learn more about ATG10 Rabbit anti-Human, Polyclonal, Invitrogen 100 µL; Unconjugated 100 µL; Unconjugated.
Shop a large selection of Immunohistochemistry (IHC) products and learn more about PNOC Rabbit anti-Human, Mouse, Rabbit, Rat, Polyclonal Antibody, Abnova 100µg; Unlabeled.
... antilymphocyte sera, monoclonal antibodies against Tlymphocytes). He has been interested in the mechanisms and treatments of ...
"Improved graft survival after treatment with Bordetella and anti-lymphocyte serum". Nature. 222 (5198): 1083-5. Bibcode: ... Ptak W, Porwit-Bóbr Z, Chlap Z (1970). "Transformation of hamster macrophages into giant cells with antimacrophage serum". ...
Peter Medawar gave a lecture entitled "Anti-lymphocyte serum" in May 1967; Henry Harris discussed "The expression of genetic ...
Among these contributions, Woodruff's work with anti-lymphocyte serum has led to its wide use to reduce rejection symptoms in ... Woodruff also commenced work on antilymphocyte serum for immunosuppression, with little initial success. While in Aberdeen, ...
Later during the treatment, some patients develop serum sickness or immune complex glomerulonephritis. Serum sickness arises ... The antilymphocyte (ALG) and antithymocyte antigens (ATG) are being used. They are part of the steroid-resistant acute ... As of March 2005, there are two preparations available to the market: Atgam, obtained from horse serum, and Thymoglobuline, ... It is possible to diminish their toxicity by using highly purified serum fractions and intravenous administration in the ...
Since the discovery of a link between antilymphocyte serum (ALS) and lymphocyte depletion by Metchnikoff in 1899, various ... Antithymocyte globulin (ATG) was originally developed as one of various tested preparations of antilymphocyte globulin (ALG) ... leading to testing of ATG derived from rabbit serum. Thymoglobulin was the first commercial rabbit-derived ATG to be introduced ...
... immune sera MeSH D12.776.377.715.548.114.573.203 - antilymphocyte serum MeSH D12.776.377.715.548.114.580 - immunoconjugates ...
... immune sera MeSH D12.776.124.486.485.114.573.203 - antilymphocyte serum MeSH D12.776.124.486.485.114.573.601 - antitoxins MeSH ... immune sera MeSH D12.776.124.790.651.114.573.203 - antilymphocyte serum MeSH D12.776.124.790.651.114.580 - immunoconjugates ...
... serum MeSH A12.207.152.846.500 - immune sera MeSH A12.207.152.846.500.203 - antilymphocyte serum MeSH A12.207.180 - body fluid ...
... immune sera MeSH D20.215.401.203 - antilymphocyte serum MeSH D20.215.535 - menotropins MeSH D20.215.659 - picibanil MeSH ...
... (ALG) is an infusion of animal- antibodies against human T cells which is used in the treatment of ... The product was manufactured by Upjohn and Merieux, as well as the Schweizerisches Serum- und Impfinstitut in Bern, the latter ... "Guillain Barré syndrome precipitated by the use of antilymphocyte globulin in the treatment of severe aplastic anaemia". J. ... Treatment of aplastic anaemia by antilymphocyte glubulin with and without allogeneic bone marrow infusions, in Lancet (1977) 2: ...
When he subsequently collected serum from these Guinea pigs and injected it into normal mice he observed a marked depletion in ... A similar trial of anti-lymphocyte globulin showed a trend in reduction of aGVH that was not statistically significant, but a ...
Additionally, blood serum should be tested for the presence of viruses, including HIV, hepatitis B and C, cytomegalovirus (CMV ... They may also be treated with anti-lymphocyte antibodies (anti-thymocyte globulin, alemtuzumab), irradiation directed against ... and serum pH and lactate levels measured for evidence of intestinal ischemia. The patient's immune system is strongly modulated ...
Negative sera from patients with other autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis and multiple ... First-line treatment for aplastic anaemia consists of immunosuppressive drugs, typically either anti-lymphocyte globulin or ... Corticosteroids are generally ineffective, though they are used to ameliorate serum sickness caused by ATG. Normally, success ... revealed more than 30 potential specific candidate autoantigens after serologic screening of a fetal liver library with sera ...
Serum target. (noncellular). *Complement component 5 *Eculizumab. *TNF *Adalimumab. *Afelimomab. *Certolizumab pegol ...
It has a serum half-life of 9.5 days and can be detected in serum 8 weeks after infusion treatment.[25] ...
Serum target. (noncellular). *Complement component 5 *Eculizumab. *TNF *Adalimumab. *Afelimomab. *Certolizumab pegol ...
Anti-lymphocyte globulin (ALG). *Monoclonal anti-CD20 antibodies *Rituximab. Blood transfer[edit]. Cases refractory to ...
Serum target. (noncellular). *Complement component 5 *Eculizumab. *TNF *Adalimumab. *Afelimomab. *Certolizumab pegol ...
Wistar rats thus first received FSC(SD) tissue as intrathymic grafts coupled with single-dose, anti- lymphocyte serum (ALS) ... Theele, D. P. ; Reier, P. J. / Immunomodulation with intrathymic grafts or anti-lymphocyte serum promotes long-term intraspinal ... Wistar rats thus first received FSC(SD) tissue as intrathymic grafts coupled with single-dose, anti- lymphocyte serum (ALS) ... Wistar rats thus first received FSC(SD) tissue as intrathymic grafts coupled with single-dose, anti- lymphocyte serum (ALS) ...
Fekete B, Petrányi G, Szegedi G, Szabó G. Connection between the anti-organ and anti-nuclear titres of antilymphocyte sera and ... T1 - Connection between the anti-organ and anti-nuclear titres of antilymphocyte sera and their inhibitory effect on skin graft ... Connection between the anti-organ and anti-nuclear titres of antilymphocyte sera and their inhibitory effect on skin graft ... Connection between the anti-organ and anti-nuclear titres of antilymphocyte sera and their inhibitory effect on skin graft ...
Antilymphocyte Serum/therapeutic use*. *Cricetinae. *Histocytochemistry. *Immunity, Cellular. *Injections, Intraperitoneal. * ... in the severity of Mycoplasma pneumoniae-induced pneumonia in hamsters by immunosuppressive treatment with antithymocyte sera. ...
Antilymphocyte Serum. Daclizumab. Immunoglobulin G. Anti-Inflammatory Agents. Antiemetics. Autonomic Agents. Peripheral Nervous ... To achieve serum level of 8-10 ng/ml.. Drug: Dexamethasone 100 mg intra-operatively, and 25 mg every 6h post-operatively for ... To achieve serum level of 8-10 ng/ml.. Drug: Dexamethasone 100 mg intra-operatively, and 25 mg every 6h post-operatively for ...
Antilymphocyte Serum. Immunosuppressive Agents. Immunologic Factors. Physiological Effects of Drugs. Calcineurin Inhibitors. ... Quantification of serum and urine M protein and serum free light chain analyses for patients with myeloma (Days 35, 70, 100, ... Contraindication to therapy with any one of the proposed agents (e.g., history of allergy to horse serum in ATG). ...
Antilymphocyte Serum. Rituximab. Fludarabine. Clofarabine. Mycophenolic Acid. Vidarabine. Immunosuppressive Agents. Immunologic ... Serum glutamate pyruvate transaminase (SGPT)/bilirubin , / = to 2.0 x normal (Myeloablative Regimen 4, Reduced Intensity ...
Antilymphocyte Serum. Fludarabine. Vidarabine. Immunosuppressive Agents. Immunologic Factors. Physiological Effects of Drugs. ... serum total bilirubin , 2x upper limit of normal for age as per local laboratory; ALT and AST , 4x upper limit of normal for ... age as per local laboratory; c) renal: serum creatinine , 2x upper limit of normal for age (as per local laboratory). d) ...
Lipemic serum (blood with high levels of fat or lipids. * Haemolyzed serum (blood where haemoglobin is separated from the red ... Anti-lymphocyte antibodies * Anti-collagen antibodies (found in gay men haemophiliacs Africans of both sexes and people with ... Serum-positive for rheumatoid factor antinuclear antibody (both found in rheumatoid arthritis and other autoantibodies * ...
Ogawa, N, List, JF, Habener, JF, Maki, T. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum ... In a study by Ogawa et al., the treatment of overtly diabetic NOD mice with anti-lymphocyte serum (ALS) abrogated autoimmunity ... Nonstandard abbreviations used: ALS, anti-lymphocyte serum; BMP4, bone morphogenetic protein 4; GIP, glucose-dependent ... Seabergs PMP-derived cells were grown instead in the serum-free medium conditions normally used for neural stem cell culture ( ...
Donor and recipient pretransplant conditioning with nonlethal radiation and antilymphocyte serum improves the graft survival in ... Donor and recipient pretransplant conditioning with nonlethal radiation and antilymphocyte serum improves the graft survival in ... Donor and recipient pretransplant conditioning with nonlethal radiation and antilymphocyte serum improves the graft survival in ... title = "Donor and recipient pretransplant conditioning with nonlethal radiation and antilymphocyte serum improves the graft ...
Suppression of microfilaricidal activity of diethylcarbamazine by anti-lymphocyte serum in Suppression of microfilaricidal ... Antilymphocyte Serum Language: English Journal: Southeast Asian J Trop Med Public Health Year: 1977 Type: Article ... Animals , Antilymphocyte Serum/pharmacology , Diethylcarbamazine/antagonists & inhibitors , Filariasis/drug therapy , ...
Antilymphocyte Serum / therapeutic use* * Biopsy * Graft Rejection / immunology * Graft Rejection / pathology * Hepatitis C / ...
Antilymphocyte Serum / therapeutic use* * Graft Rejection / epidemiology * Histocompatibility Testing * Humans * ...
Antilymphocyte Serum. Cytotoxicity Tests, Immunologic. Female. Gestational Age*. Humans. Immunity, Cellular*. Lymphocytes / ... 8906258 - Activated cellular immunity and decreased serum tryptophan in healthy pregnancy.. 7312228 - Acceleration of fetal ...
What is antilymphocyte globulin? Meaning of antilymphocyte globulin medical term. What does antilymphocyte globulin mean? ... Looking for online definition of antilymphocyte globulin in the Medical Dictionary? antilymphocyte globulin explanation free. ... antilymphocyte globulin (ALG) the gamma globulin fraction of antilymphocyte serum; used as an immunosuppressant in organ ... antilymphocyte globulin. Antilymphocyte serum Clinical immunology A polyclonal antiserum raised in one species of animals ...
Immunologic Tolerance and Chimerism Produced Across the H-2 Locus with Adult Thymectomy and Anti-Lymphocyte Serum", Ann. NY ... Immunologic Tolerance and Chimerism Produced Across the H 2 Locus with Adult Thymectomy and Anti Lymphocyte Serum , Ann. NY ... Monaco et al., 1966, "Studies on Heterologous Anti-lymphocyte Serum in Mice. III. ... Monaco et al., 1966, Studies on Heterologous Anti lymphocyte Serum in Mice. III. ...
2. antilymphocyte serum. ALL. 1 abbreviation for acute lymphocytic leukemia. 2 abbreviation for acute lymphoid leukemia. ...
THE PREPARATION OF ANTILYMPHOCYTE SERUM BY TRANSPLANTATION OF LYMPHOID HETEROGRAFTS TO THE ANTERIOR CHAMBER OF THE RABBIT EYE. ...
Immunosuppression was by Azathioprine, prednisolone and antilymphocyte serum. His initial progress was excellent but three ... Immunosuppression was by Azathioprine, prednisolone and antilymphocyte serum. His initial progress was excellent but three ...
... antilymphocyte sera, monoclonal antibodies against Tlymphocytes). He has been interested in the mechanisms and treatments of ...
"Improved graft survival after treatment with Bordetella and anti-lymphocyte serum". Nature. 222 (5198): 1083-5. Bibcode: ... Ptak W, Porwit-Bóbr Z, Chlap Z (1970). "Transformation of hamster macrophages into giant cells with antimacrophage serum". ...
ATG is a polyclonal antilymphocyte serum. It contains specific antibodies that act directly against a variety of T cell surface ... serum level of creatinine elevated by more than 15%; (3) increased urinary protein; (4) color Doppler ultrasound indicating an ...
Re-treatment of aplastic anemia with antithymocyte globulin or antilymphocyte serum. Am J Med. 1988 Apr. 84(4):678-82. [Medline ... Treatment of aplastic anemia with an investigational antilymphocyte serum prepared in rabbits. Am J Med Sci. 1994 Dec. 308(6): ... Liu H, Mihara K, Kimura A, Tanaka K, Kamada N. Induction of apoptosis in CD34+ cells by sera from patients with aplastic anemia ... Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood. 1987 Oct. 70(4):1046-52 ...
Studies on heterologous anti-lymphocyte serum in mice. II. Effect on the immune response. J. Immunol. 96:229. ... and IL-2 and IFN-γ produced in primary response to SEB stimulation are not detected in the serum of adoptively transferred ...
The Effect of Antilymphocyte Serum on Experimental Allergic Encephalomyelitis. Annals of Internal Medicine; 68 (5): 1141 ...
Antilymphocyte Serum/pharmacology. MESH. Cells, Cultured. MESH. Herpesvirus 4, Human/immunology. MESH. ... Immobilization of Raji cells on surface coated with anti-lymphocyte globulin (ALG) at low cell densities lead to the synthesis ... Immobilization of Raji cells on surface coated with anti-lymphocyte globulin (ALG) at low cell densities lead to the synthesis ... The spontaneous and induced synthesis of Epstein-Barr virus antigens in Raji cells immobilized on surface coated with anti-lymphocyte ...
Antilymphocyte Immunoglobulin Horse. Uman-Gamma. Immune Globulin Normal. Uman-Serum. Plasma Protein Fraction. ...
Adaptation of skin allografts in mice treated with antilymphocyte serum. Transplantation 13:27. ...
Studies on heterologous anti-lymphocyte serum in mice. II. Effect on the immune response. J. Immunol. 96:229-238. ... vol/vol heat-inactivated normal rabbit serum, and 0.1% wt/vol sodium azide. Cells were incubated for 45 min at 4°C with ...
  • Examples are transferrin, a beta 1 -globulin that transports iron, and alpha 1 -antitrypsin, an acute phase reactant that inhibits serum proteases. (thefreedictionary.com)
  • immune human serum globulin immune globulin (def. (thefreedictionary.com)
  • immune serum globulin immune g. (def. (thefreedictionary.com)
  • Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. (medscape.com)
  • According to a report on Chinese news website Sina.com , shortly after Lexuan was diagnosed with aplastic anaemia three years ago, doctors were able to stablise her condition using Antilymphocyte Globulin, which is serum from blood that contains anti-bodies that bind to human T cells. (dailymail.co.uk)
  • Human serum sickness: a prospective analysis of 35 patients treated with equine anti-thymocyte globulin for bone marrow failure. (mdedge.com)
  • Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: case report and literature review. (mdedge.com)
  • Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. (mdedge.com)
  • Tatum AH, Bollinger RR, Sanfilippo F. Rapid serologic diagnosis of serum sickness from antithymocyte globulin therapy using enzyme immunoassay. (mdedge.com)
  • Cutaneous manifestations of serum sickness in patients receiving antithymocyte globulin. (mdedge.com)
  • Animal serum was formerly used for passive immunization against some infectious diseases but now has very limited use in antitoxins, monoclonal antibodies, and antilymphocyte globulin. (tabers.com)
  • the action of immunosuppressants (cyclosporin, antilymphocyte sera, monoclonal antibodies against Tlymphocytes). (wikipedia.org)
  • And from there I went to antilymphocyte serum monoclonal antibodies, tolerance, xenotransplantation over the years, and here we are. (asts.org)
  • The induction agent has evolved over the years from Minnesota ALG, to monoclonal antilymphocyte antibodies OKT3 and thymoglobulin. (scirp.org)
  • Theele, DP & Reier, PJ 1996, ' Immunomodulation with intrathymic grafts or anti-lymphocyte serum promotes long-term intraspinal allograft survival ', Cell Transplantation , vol. 5, no. 2, pp. 243-255. (elsevier.com)
  • Herein, we evaluate the potential advantage of donor-specific bone marrow infusions in donor and or recipient preconditioned with total body irradiation and or antilymphocyte serum (ALS) on the incidence of GVHD and rejection after small bowel transplantation. (elsevier.com)
  • Treatment with polyclonal antilymphocyte globulins induces depletion of circulating CD3+CD4+CD28− T-cells in transplant recipients.Prevalences of peripheral circulating CD3+CD4+CD28− T-cells in 16 age- and sex-matched healthy controls, 5 allograft recipients before and 6 hours after the application of ATG-F and 11 control patients before and 6 hours after organ transplantation. (nih.gov)
  • Epstein-Barr virus [EBV] serostatus of the recipient and the cytomegalovirus [CMV] sero-status of the recipient and the potential donor) and the principal risk factor after transplantation (immunosuppression with antilymphocyte antibody), we analyzed the findings for the first 381 consecutive adult nonrenal transplant recipients seen at Mayo Clinic. (elsevier.com)
  • Nowadays most immunosuppressive regimens used early after transplantation are based on CsA, usually combined with other pharmacological drugs and, in many instances, also with biological antilymphocyte agents. (uninet.edu)
  • The author shows that the use of antilymphocyte serum (ALS), normally used following organ transplantation, is capable of inducing biological and clinical manifestations which are analogous to those of patients suffering from AIDS. (bireme.br)
  • Wistar rats thus first received FSC(SD) tissue as intrathymic grafts coupled with single-dose, anti- lymphocyte serum (ALS) ablation of the circulating host T-cell population. (elsevier.com)
  • Suppression of microfilaricidal activity of diethylcarbamazine by anti-lymphocyte serum in cotton rat filariasis. (bvsalud.org)
  • Monaco AP, Wood ML and Russel PS (1966) Studies on heterologous anti-lymphocyte serum in mice: III. (springer.com)
  • Immunologic tolerance and chimerism produced across the H-2 locus with adult thymectomy and anti-lymphocyte serum. (springer.com)
  • Anti-lymphocyte serum is not the only suspect-tumors have also occurred in patients treated with prednisone and Imuran alone. (indigo.ca)
  • We investigated the susceptibility of ASCs and BM-MSCs to anti-lymphocyte serum (ALS) and tacrolimus. (uzh.ch)
  • The fulminating disease, which occurs in adult mice after intracerebral inoculation with LCM virus, can be ameliorated by several treatments known to impair the immune response of the host, such as X-rays 6 , amethopterin 7 , thymectomy 8 and anti-lymphocyte serum 9 . (nature.com)
  • Glathe, H et al, Evidence of Tumorigenic Activity of Candidate Cell Substrate in Vaccine Production by the Use of Anti-Lymphocyte Serum , Development Biol Std, 1977, 34:145-148. (bibliotecapleyades.net)
  • Connection between the anti-organ and anti-nuclear titres of antilymphocyte sera and their inhibitory effect on skin graft rejection in mice. (elsevier.com)
  • We found that patient sera with elevated levels of TRIM72 autoantibodies suppress sarcolemmal resealing in healthy skeletal muscle, and depletion of TRIM72 antibodies from these same serum samples rescues sarcolemmal repair capacity. (jci.org)
  • 07). The incidence of steroid-resistant rejection requiring antilymphocyte therapy (OKT3 or ATGAM) was 13%, and was not different between the double and triple therapy groups. (nih.gov)
  • Serum sickness is a hypersensitivity reaction to proteins in antiserum derived from nonhuman animal sources and can be seen in patients being treated with antiserum to prevent transplant rejection. (mdedge.com)
  • We present a case of a 35-year-old man with presumed serum sickness after receiving thymoglobulin for the treatment of acute cellular rejection of a heart transplant. (mdedge.com)
  • Serum sickness can be seen in patients treated with thymoglobulin to prevent transplant rejection. (mdedge.com)
  • Acute rejection in human renal allografts is manifested as an increase in serum creatinine levels associated with typical biopsy findings. (asnjournals.org)
  • 1976) Possible active enhancement of a human cadaver renal allograft with antilymphocytic serum (ALS) and donor bone marrow: Case report of an initial attempt. (springer.com)
  • A prospective clinical and immunologic analysis of patients with serum sickness. (mdedge.com)
  • Initiation of cyclosporine treatment post-transplant was delayed until the serum creatinine was ≤2.5 mg/dl. (scirp.org)
  • Liu H, Mihara K, Kimura A, Tanaka K, Kamada N. Induction of apoptosis in CD34+ cells by sera from patients with aplastic anemia. (medscape.com)
  • The increase in serum creatinine levels, caused by a decrease in the GFR, often responds to pulse steroid therapy or antilymphocyte antibody therapy. (asnjournals.org)
  • In this study we evaluated the influence of polyclonal antilymphocyte globulins (ATG-Fresenius, ATG-F) on CD4(+)CD28(-) T-cells in vivo and in vitro. (nih.gov)
  • 1986) Prolongation of renal allograft survival in antilymphocyte-serumtreated dogs by postoperative injection of density-gradientfractionated donor bone marrow. (springer.com)
  • The mean serum creatinine was 1.8 +/- 0.8 mg/dl. (nih.gov)
  • Serum sickness may display variable clinical presentations. (mdedge.com)
  • Serum sickness can display multiple cutaneous manifestation, thus making it an important entity for dermatologists. (mdedge.com)
  • Selection of treatment of cefaclor-associated urticarial, serum sickness-like reactions and erythema multiforme by emergency pediatricians: lack of a uniform standard of care. (mdedge.com)
  • Severe serum sickness reaction to oral and intramuscular penicillin. (mdedge.com)
  • Finger E, Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. (mdedge.com)
  • Tatum AJ, Ditto AM, Patterson R. Severe serum sickness-like reaction to oral penicillin drugs: three case reports. (mdedge.com)
  • Serum sickness can also occur after administration of penicillins and other drugs. (tabers.com)
  • The plasma globulins are separated into five fractions by serum protein electrophoresis (SPE). (thefreedictionary.com)
  • Apoptotic effects of antilymphocyte globulins on human pro-inflammatory CD4+CD28- T-cells. (nih.gov)
  • The serum, administered to humans with transplanted organs, in some way inactivates lymphocyte cells. (thefreedictionary.com)
  • strabismus, nystagmus, and optic atrophy can also occur.etiologyperoxisomal acyl-coa oxidase deficiency is caused by mutations in the acox1 gene (17q25.1) encoding peroxisomal straight-chain acyl-coa oxidase.diagnostic methodsdiagnosis is based on laboratory studies revealing increased serum very-long chain fatty acids (vlcfa) and markedly reduced acyl-coa oxidase activity in fibroblasts. (malacards.org)
  • False-positives occur when antilymphocyte antibodies are present. (labcorp.com)
  • For the measurement of C3d-bound circulating immune complexes (CIC) present in human plasma or serum. (labcorp.com)
  • In another immunosuppressive method, human lymphocytes are injected into horses, stimulating the animals to produce antilymphocyte serum. (thefreedictionary.com)
  • We hybridized 35 and 51 ICL patients' sera to a 9,000 human proteome array and to a 128 known autoantigens array, respectively. (jci.org)
  • Antithymocyte immunoglobulin from rabbit serum is classified in L04AA04. (whocc.no)
  • Reduction in the severity of Mycoplasma pneumoniae-induced pneumonia in hamsters by immunosuppressive treatment with antithymocyte sera. (nih.gov)
  • We identified autoantibodies against TRIM72 (also known as MG53), a muscle-enriched membrane repair protein, in IIM patient sera and in our mouse model of IIM by ELISA. (jci.org)
  • The Effect of Antilymphocyte Serum on Experimental Allergic Encephalomyelitis. (annals.org)
  • Serum from ALS-treated animals was added to cell cultures. (uzh.ch)
  • Serum markers of cardiomyocyte injury (troponin, creatine kinase-myocardial band) are almost always elevated, and brain natriuretic peptide might be elevated in more than half of the cases (though it is chronically elevated in patients with cancer). (acc.org)
  • 13% of the cadaveric kidneys were from pediatric donors less than 3 years of age and were transplanted en bloc. (nih.gov)